Gengos Andrew
SEC-identified person · CIK 1563623 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Turn Therapeutics Inc. TTRX | Director | filed 2025 - 2026 |
| Terns Pharmaceuticals, Inc. TERN | Chief Financial Officer | filed 2025 - 2026 |
| Leonabio, Inc. LONA | See Below | filed 2023 - 2024 |
| Cyteir Therapeutics, Inc. CYT | Chief Business Officer | filed 2021 - 2022 |
| Synlogic, INC. SYBX | See Remarks | filed 2017 - 2018 |
| Immunocellular Therapeutics, Ltd. IMUC | Director · President and CEO | filed 2012 - 2017 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.